TNGX Stock: Price, Earnings History and SEC Filings
Tango Therapeutics, Inc. (TNGX) last traded at $22.72, up 0.84% on the latest session and down 8.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.37 against an analyst estimate of $-0.31, a miss of 19.4%.
$22.72 +0.84%
1 month-8.94%
52-week high$34.39
52-week low$7.37
Volume5.28M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TNGX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 11, 2026 | $-0.37 | $-0.31 | -19.35% |
| Mar 2026 | May 13, 2026 | $-0.32 | $-0.32 | +0.00% |
| Dec 2025 | Mar 5, 2026 | $-0.29 | $-0.31 | +6.45% |
| Sep 2025 | Nov 4, 2025 | $0.13 | $0.01 | +1200.00% |
TNGX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for TNGX
SEC filing data is not available right now. You can search for TNGX on SEC EDGAR.
TNGX news
- Tango Therapeutics (TNGX) Following Trial Update Has Its Valuation Story Back In FocusOct 28, 2026 · finance.yahoo.com
- Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is SayingOct 28, 2026 · seekingalpha.com
- Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?Oct 28, 2026 · finance.yahoo.com
- TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study DataOct 26, 2026 · finance.yahoo.com
- Tango Therapeutics Highlights Positive Vopimetostat Combination DataOct 24, 2026 · theglobeandmail.com
- Tango Therapeutics Just Improved On This 'Unprecedented' Cancer DrugOct 23, 2026 · finance.yahoo.com
- Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response RateOct 23, 2026 · marketbeat.com
- Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?Oct 23, 2026 · finance.yahoo.com
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc. (TNGX) is a US-listed public company on Nasdaq.